EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK – STAT3 Signaling

Melika Amelimojarad iD, Mandana Amelimojarad iD, Alireza Pourmahdian, Zhang Lu

Cancer Medicine · 2026

DOI: 10.1002/cam4.71543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Melika Amelimojarad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, School of Medicine, Iran University of Medical Science, Tehran, Iran. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Coenzyme A Ligases, STAT3 Transcription Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapies. Reprogrammed lipid metabolism, driven by upregulated de novo lipogenesis, is a key tumorigenic mechanism. The enzyme ACSL3 is strongly correlated with poor HCC prognosis, positioning it as a potential therapeutic target. Material and Methods ACSL3 expression was assessed in vivo and ex vivo using comparative analysis. Bioinformatic investigations, including gene set enrichment analysis (GSEA) and KEGG pathway analysis, were employed to identify signaling pathways and biological processes associated with ACSL3 overexpression.

Results

ACSL3 expression was consistently elevated in HCC models. Enrichment analyses revealed that high ACSL3 levels are associated with activation of the STAT3 signaling pathway and upregulation of key lipogenic enzymes, suggesting a feedforward oncogenic loop. Predictive data also indicate a correlation between ACSL3 expression and the immune checkpoint regulator PD‐L1.

Conclusion

These findings underscore ACSL3 as a significant biomarker and candidate therapeutic target in HCC. Its role bridges dysregulated lipid metabolism with oncogenic signaling and immune evasion, warranting further investigation into ACSL3‐targeted strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCoenzyme A LigasesSTAT3 Transcription FactorJanus KinasesHumansSignal TransductionAnimalsLong-Chain-Fatty-Acid-CoA LigaseLipid MetabolismGene Expression Regulation, NeoplasticMiceCarcinogenesisBiomarkers, TumorCell Line, Tumor

Stichwörter der Autor:innen

ACSL3LDslipid metabolismliver cancer

Substanzen

Coenzyme A LigasesSTAT3 Transcription FactorLong-Chain-Fatty-Acid-CoA LigaseJanus KinasesSTAT3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Life Science, School of Medicine, Iran University of Medical Science, Tehran, Iran.
  • Department of Life Sciences, Liaoning University, Shenyang, China.

ORCID-Profile: Melika Amelimojarad, Mandana Amelimojarad

Zitieren

APA

Amelimojarad, M., Amelimojarad, M., Pourmahdian, A., & Lu, Z. (2026). ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK – STAT3 Signaling. Cancer Medicine. https://doi.org/10.1002/cam4.71543

Vancouver

Amelimojarad M, Amelimojarad M, Pourmahdian A, Lu Z. ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK – STAT3 Signaling. Cancer Medicine. 2026. doi:10.1002/cam4.71543

BibTeX
@article{Amelimojarad2026,
  author = {Amelimojarad, Melika and Amelimojarad, Mandana and Pourmahdian, Alireza and Lu, Zhang},
  title = {ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK – STAT3 Signaling},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71543}
}
Kostenlos starten →